Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory B-cell Malignancies.
Conditions: CLL/SLL; Waldenstrom Macroglobulinemia; Follicular Lymphoma; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Hairy Cell Leukemia Intervention: Drug: LP-168 Sponsor: Newave Pharmaceutical Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2021 Category: Research Source Type: clinical trials
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Conditions: CLL/SLL; Waldenstrom Macroglobulinemia; Follicular Lymphoma; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Hairy Cell Leukemia Intervention: Drug: LP-168 Sponsor: Newave Pharmaceutical Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2021 Category: Research Source Type: clinical trials
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory B-cell Malignancies.
Conditions: CLL/SLL; Waldenstrom Macroglobulinemia; Follicular Lymphoma; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Hairy Cell Leukemia Intervention: Drug: LP-168 Sponsor: Newave Pharmaceutical Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2021 Category: Research Source Type: clinical trials
Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
Conditions: Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Waldenstrom Macroglobulinemia Intervention: Sponsors: Assistance Publique - Hôpitaux de Paris; INSERM UMR 1163 Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2021 Category: Research Source Type: clinical trials